Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer

Background/Aim: Ra-223 is a therapeutic agent for bone metastatic castration-resistant prostate cancer (mCRPC). We examined the efficacy of a treatment method using Ra-223 together with ethinylestradiol (EE). Patients and Methods: Patients who received Ra-223 three or more times were included and two groups (with or without EE) were compared retrospectively. Results: Eighteen patients were treated with Ra-223 and EE concomitantly (EstRadium therapy) and 13 patients were treated with Ra-223 alone or Ra-223 and agents other than EE (non-EstRadium therapy). The number of patients with decreased serum prostate-specific antigen level was significantly higher in the EstRadium therapy group than in the non-EstRadium therapy group (p=0.029). Conclusion: The combination of Ra-223 and EE, compared to Ra-223 alone, is an effective treatment option for bone mCRPC patients, in terms of PSA response.

[1]  F. Saad,et al.  Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. , 2021 .

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  Tetsuya Shindo,et al.  Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer , 2020, Cancer medicine.

[4]  H. Yaegashi,et al.  Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer , 2020, AntiCancer Research.

[5]  E. Antonarakis,et al.  Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. , 2019, Translational andrology and urology.

[6]  D. George,et al.  Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer , 2019, American journal of clinical oncology.

[7]  F. Saad,et al.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[8]  Y. Shida,et al.  Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men , 2018, International journal of urology : official journal of the Japanese Urological Association.

[9]  R. Vessella,et al.  Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models , 2017, Clinical Cancer Research.

[10]  A. Semjonow,et al.  Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer , 2016, BMC Cancer.

[11]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[12]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[13]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[14]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[15]  K. Izumi,et al.  Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. , 2010, Anticancer research.

[16]  W. Oh,et al.  The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. , 2009, Clinical genitourinary cancer.

[17]  S. Nilsson,et al.  High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.

[18]  K. Ohama,et al.  [Estrogen and bone metabolism]. , 2003, Clinical calcium.

[19]  J. Roeske,et al.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  C. Kerr.  (223)Ra targets skeletal metastases and spares normal tissue. , 2002, The Lancet. Oncology.

[21]  G. Henriksen,et al.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.

[22]  J. Parry,et al.  Diethylstilboestrol: the binding and effects of diethylstilboestrol upon the polymerisation and depolymerisation of purified microtubule protein in vitro. , 1985, Carcinogenesis.

[23]  F. Saad,et al.  Enzalutamide in Metastatic Prostate Cancer before Chemotherapy , 2014 .

[24]  P. Chambon,et al.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. , 2007, Cell.